Teitur Trophics Raises Eur 28M In Series A Financing To Advance The Development And Treatment For Neurodegenerative Diseases
Amount Raised
€28 Million
Round Type
Series A
ÅrhusBiotechnologyHealth CareTherapeuticsInvestors
Description
Teitur Trophics ("Teitur"), a biotech company dedicated to developing new treatments for patients suffering from neurodegenerative diseases, today announces the completion of a €28M Series A financing. The financing was co-led by Sunstone Life Science Ventures and Sound Bioventures, with participation from new investors, Industrifonden, Innovestor's Life Science Fund and P53 Invest. The proceeds will enable Teitur to progress its lead drug candidate, TT-P34, from candidate selection into clinical development, including a Phase 1b clinical study in neurodegenerative diseases.
Quick answer
Teitur Trophics raised €28 Million in a Series A round, dated March 14, 2023. Investors: P53 Invest, Innovestor's Life Science Fund, Industrifonden, Sound Bioventures and Sunstone Life Science Ventures. Teitur Trophics is based in Århus, Central Denmark Region, Denmark.
- How much did Teitur Trophics raise?
- Teitur Trophics raised €28 Million in a Series A round on March 14, 2023.
- Who invested in Teitur Trophics?
- P53 Invest, Innovestor's Life Science Fund, Industrifonden, Sound Bioventures and Sunstone Life Science Ventures are named as investors in this round.
- What does Teitur Trophics do?
- Teitur Trophics, founded by Simon Molgaard, Anders Dalby, Mathias Ollendorff and Simon Glerup, is a biotech company that targets neurodegenerative diseases, based in Aarhus, Denmark.
- Where is Teitur Trophics based and how big is it?
- Teitur Trophics is based in Århus, Central Denmark Region, Denmark.
- Who are the decision-makers at Teitur Trophics?
- Fundz holds 1 contact at Teitur Trophics. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Therapeutics and Biotechnology around the same time
Companies in the same sectors as Teitur Trophics that raised within 45 days of this round, from Fundz verified event records.
- HCW Biologics raised $26M (Debt Financing) on April 27, 2023.
- Convergent Therapeutics raised $29M on April 27, 2023.
- Radiant raised $6.3M (Seed) on April 26, 2023.
- Mezzion Pharma raised $40M (Funding Round) on April 25, 2023.
- Radiant raised $8M (Seed) on April 25, 2023.
- Phio Pharmaceuticals raised $4M (Seed) on April 20, 2023.
Who to call at Teitur Trophics, and when
A new round usually means Teitur Trophics is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Teitur Trophics raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Teitur Trophics, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Teitur Trophics. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Teitur Trophics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Funding Insights
What this usually meansTeitur Trophics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.